Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 201

1.

Outcomes and characteristics of ertapenem-nonsusceptible Klebsiella pneumoniae bacteremia at a university hospital in Northern Taiwan: a matched case-control study.

Liu SW, Chang HJ, Chia JH, Kuo AJ, Wu TL, Lee MH.

J Microbiol Immunol Infect. 2012 Apr;45(2):113-9. doi: 10.1016/j.jmii.2011.09.026. Epub 2011 Dec 11.

2.

Risk factors and clinical significance of ertapenem-resistant Klebsiella pneumoniae in hospitalised patients.

Orsi GB, García-Fernández A, Giordano A, Venditti C, Bencardino A, Gianfreda R, Falcone M, Carattoli A, Venditti M.

J Hosp Infect. 2011 May;78(1):54-8. doi: 10.1016/j.jhin.2011.01.014. Epub 2011 Mar 30.

PMID:
21450365
3.

Characterization of carbapenem-nonsusceptible Klebsiella pneumoniae bloodstream isolates at a Taiwanese hospital: clinical impacts of lowered breakpoints for carbapenems.

Lee NY, Wu JJ, Lin SH, Ko WC, Tsai LH, Yan JJ.

Eur J Clin Microbiol Infect Dis. 2012 Aug;31(8):1941-50. doi: 10.1007/s10096-011-1525-2. Epub 2012 Jan 18.

PMID:
22249422
4.

Ceftazidime-resistant Klebsiella pneumoniae bloodstream infection in children with febrile neutropenia.

Ariffin H, Navaratnam P, Mohamed M, Arasu A, Abdullah WA, Lee CL, Peng LH.

Int J Infect Dis. 2000;4(1):21-5.

PMID:
10689210
5.

Molecular epidemiology and risk factors of bloodstream infections caused by extended-spectrum beta-lactamase-producing Klebsiella pneumoniae A case-control study.

Mosqueda-Gómez JL, Montaño-Loza A, Rolón AL, Cervantes C, Bobadilla-del-Valle JM, Silva-Sánchez J, Garza-Ramos U, Villasís-Keever A, Galindo-Fraga A, Palacios GM, Ponce-de-León A, Sifuentes-Osornio J.

Int J Infect Dis. 2008 Nov;12(6):653-9. doi: 10.1016/j.ijid.2008.03.008. Epub 2008 Jun 3.

6.

Carbapenem therapy for bacteremia due to extended-spectrum-β-lactamase-producing Escherichia coli or Klebsiella pneumoniae: implications of ertapenem susceptibility.

Lee NY, Lee CC, Huang WH, Tsui KC, Hsueh PR, Ko WC.

Antimicrob Agents Chemother. 2012 Jun;56(6):2888-93. doi: 10.1128/AAC.06301-11. Epub 2012 Mar 19.

7.

Clinical characteristics and outcome of patients with community-onset Klebsiella pneumoniae bacteremia requiring intensive care.

Tseng CP, Wu HS, Wu TH, Lin YT, Fung CP.

J Microbiol Immunol Infect. 2013 Jun;46(3):217-23. doi: 10.1016/j.jmii.2012.06.001. Epub 2012 Jul 24.

8.

Risk factors of carbapenem-resistant Klebsiella pneumoniae infections: a matched case control study.

Falagas ME, Rafailidis PI, Kofteridis D, Virtzili S, Chelvatzoglou FC, Papaioannou V, Maraki S, Samonis G, Michalopoulos A.

J Antimicrob Chemother. 2007 Nov;60(5):1124-30. Epub 2007 Sep 20.

PMID:
17884829
9.

Clinical features of patients with carbapenem nonsusceptible Klebsiella pneumoniae and Escherichia coli in intensive care units: a nationwide multicenter study in Taiwan.

Chang YY, Chuang YC, Siu LK, Wu TL, Lin JC, Lu PL, Wang JT, Wang LS, Lin YT, Huang LJ, Fung CP.

J Microbiol Immunol Infect. 2015 Apr;48(2):219-25. doi: 10.1016/j.jmii.2014.05.010. Epub 2014 Jul 26.

11.

Impact of carbapenem resistance on the outcome of patients' hospital-acquired bacteraemia caused by Klebsiella pneumoniae.

Hussein K, Raz-Pasteur A, Finkelstein R, Neuberger A, Shachor-Meyouhas Y, Oren I, Kassis I.

J Hosp Infect. 2013 Apr;83(4):307-13. doi: 10.1016/j.jhin.2012.10.012. Epub 2013 Jan 10.

PMID:
23313086
12.

[Risk factors and prognosis in 31 patients with extended-spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae bloodstream infection].

Chen YH, Yao WZ, Wu R, Zhou QT, Liu ZY, Zhang XW.

Zhonghua Jie He He Hu Xi Za Zhi. 2008 Nov;31(11):815-9. Chinese.

PMID:
19080534
13.

Patient risk factors for outer membrane permeability and KPC-producing carbapenem-resistant Klebsiella pneumoniae isolation: results of a double case-control study.

Orsi GB, Bencardino A, Vena A, Carattoli A, Venditti C, Falcone M, Giordano A, Venditti M.

Infection. 2013 Feb;41(1):61-7. doi: 10.1007/s15010-012-0354-2. Epub 2012 Oct 16.

PMID:
23070604
14.
15.

Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae bloodstream infection: risk factors and clinical outcome.

Du B, Long Y, Liu H, Chen D, Liu D, Xu Y, Xie X.

Intensive Care Med. 2002 Dec;28(12):1718-23. Epub 2002 Oct 17.

PMID:
12447513
16.

Nosocomial extended-spectrum beta-lactamase-producing Klebsiella pneumoniae bacteremia in hemodialysis patients and the implications for antibiotic therapy.

Yang CC, Wu CH, Lee CT, Liu HT, Chen JB, Chiu CH, Chen CH, Chuang FR.

Int J Infect Dis. 2014 Nov;28:3-7. doi: 10.1016/j.ijid.2014.07.012. Epub 2014 Sep 6.

18.

Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment.

Zarkotou O, Pournaras S, Tselioti P, Dragoumanos V, Pitiriga V, Ranellou K, Prekates A, Themeli-Digalaki K, Tsakris A.

Clin Microbiol Infect. 2011 Dec;17(12):1798-803. doi: 10.1111/j.1469-0691.2011.03514.x. Epub 2011 May 20.

19.
20.

Risk factors and outcomes for bloodstream infections with extended-spectrum beta -lactamase-producing Klebsiella pneumoniae ; Findings of the nosocomial surveillance system in Hungary.

Szilágyi E, Füzi M, Böröcz K, Kurcz A, Tóth A, Nagy K.

Acta Microbiol Immunol Hung. 2009 Sep;56(3):251-62. doi: 10.1556/AMicr.56.2009.3.5.

PMID:
19789140

Supplemental Content

Support Center